نتائج البحث - "Glucagon-like Peptide-1 Receptor Agonists"

المصدر: Scottish Diabetes Research Network Epidemiology Group 2020 , ' Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland ' , Diabetes Care , vol. 43 , no. 9 , pp. 2034-2041 . https://doi.org/10.2337/dc20-0120Test

الوقت: 21st Century

العلاقة: https://discovery.dundee.ac.uk/en/publications/11798f26-74ba-42c0-97dc-5cc97e1dded2Test

الإتاحة: https://doi.org/10.2337/dc20-0120Test
https://discovery.dundee.ac.uk/en/publications/11798f26-74ba-42c0-97dc-5cc97e1dded2Test

View record in BASE

4

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

المؤلفون: Fahri Bayram, Katerina Urbancova, Capture Study Investigators, Abdullah M. Alguwaihes, Shinichiro Shirabe, Csaba Lengyel, Guillermo Dieuzeide, Ofri Mosenzon, Jose Luis A. Leon, Nicolai Rhee, Giuseppina T. Russo, Sergio Vencio, Margit S Kaltoft, Patrice Darmon, Timothy M. E. Davis, Kirsten T. Eriksen, Tianpei Hong

المساهمون: The Hebrew University of Jerusalem (HUJ), King Saud University [Riyadh] (KSU), Erciyes University, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), The University of Western Australia (UWA), Novo Nordisk Inc, NOVO NORDISK PARK, Peking University [Beijing], University of Szeged [Szeged], Novo nordisk pharma, University of Messina

المصدر: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-13 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology, 2021, 20 (1), pp.154. ⟨10.1186/s12933-021-01344-0⟩

مصطلحات موضوعية: Male, medicine.medical_specialty, Time Factors, Cross-sectional study, [SDV]Life Sciences [q-bio], Endocrinology, Diabetes and Metabolism, Prevalence, Type 2 diabetes, Non-interventional study, Risk Assessment, Glucagon-like peptide-1 receptor agonists, chemistry.chemical_compound, Interquartile range, Risk Factors, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Diseases of the circulatory (Cardiovascular) system, Original Investigation, Aged, business.industry, Odds ratio, Middle Aged, Protective Factors, medicine.disease, Prognosis, Cardiovascular disease, Confidence interval, Cross-Sectional Studies, chemistry, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Atherosclerotic cardiovascular disease, RC666-701, Female, Glycated hemoglobin, Cardiology and Cardiovascular Medicine, business, Sodium-glucose co-transporter-2 inhibitors, Demography

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0c647e392a328eb4db221b67cb91bcTest
https://doaj.org/article/67a5ab1adb4e4cf9b4f165303e5e0c48Test

5

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

المؤلفون: Grace Auld, Dilan Athauda, Christine Girges, Cate Whittlesea, Nirosen Vijiaratnam, Tian-Tian Ma, Ruth Brauer, Li Wei, Thomas Foltynie, Ian C. K. Wong

المصدر: Brain

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Parkinson's disease, medicine.medical_treatment, Dipeptidyl Peptidase 4, Disease, dipeptidyl peptidase 4 inhibitors, Rate ratio, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Glucagon-Like Peptide 1, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Longitudinal Studies, Aged, glucagon-like peptide-1 receptor agonists, Dipeptidyl-Peptidase IV Inhibitors, diabetes, business.industry, Proportional hazards model, AcademicSubjects/SCI01870, Insulin, Incidence (epidemiology), Parkinson Disease, Original Articles, Middle Aged, medicine.disease, Scientific Commentaries, humanities, United Kingdom, 030104 developmental biology, electronic health records, Diabetes Mellitus, Type 2, Parkinson’s disease, Female, AcademicSubjects/MED00310, Neurology (clinical), business, 030217 neurology & neurosurgery, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0fe28d06175c2f36887b623408ab54dTest
http://europepmc.org/articles/PMC7794498Test

6

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

المؤلفون: Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, John B. Buse, Thomas Idorn, Kenneth W. Mahaffey, Johannes F.E. Mann, Michael A. Nauck, Søren Rasmussen, Peter Rossing, Benjamin Wolthers, Bernard Zinman, Vlado Perkovic

المصدر: Shaman, A M, Bain, S C, Bakris, G L, Buse, J B, Idorn, T, Mahaffey, K W, Mann, J F E, Nauck, M A, Rasmussen, S, Rossing, P, Wolthers, B, Zinman, B & Perkovic, V 2022, ' Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes : Pooled Analysis of SUSTAIN 6 and LEADER ', Circulation, vol. 145, no. 8, pp. 575-585 . https://doi.org/10.1161/CIRCULATIONAHA.121.055459Test

مصطلحات موضوعية: glucagon-like peptide-1 receptor agonists, Male, liraglutide, semaglutide, Glucagon-Like Peptides, Liraglutide, Middle Aged, albuminuria, Diabetes Mellitus, Type 2, Physiology (medical), eGFR, Albuminuria, Humans, Female, type 2 diabetes, Cardiology and Cardiovascular Medicine, chronic kidney disease, Follow-Up Studies, Glomerular Filtration Rate